SFM
DCPH

Sphera Funds Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Sphera Funds Management’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-103,565
Closed -$5.91M – 209
2020
Q4 		$5.91M Sell
103,565
-240,400
-70% -$14.2M 0.52% 59
2020
Q3 		$17.6M Buy
343,965
+61,000
+22% +$2.99M 1.73% 14
2020
Q2 		$16.9M Buy
282,965
+163,465
+137% +$8.74M 1.59% 16
2020
Q1 		$4.92M Buy
+119,500
New +$6.63M 0.62% 35
2019
Q2 		– Sell
-115,033
Closed -$2.67M – 113
2019
Q1 		$2.67M Hold
115,033
– – 0.24% 80
2018
Q4 		$2.42M Buy
115,033
+5,000
+5% +$123K 0.27% 67
2018
Q3 		$4.26M Buy
110,033
+17,002
+18% +$628K 0.49% 58
2018
Q2 		$3.66M Buy
93,031
+52,185
+128% +$1.54M 0.5% 62
2018
Q1 		$819K Sell
40,846
-183,308
-82% -$4.64M 0.12% 89
2017
Q4 		$5.01M Buy
224,154
+149,154
+199% +$2.92M 0.59% 40
2017
Q3 		$1.42M Buy
+75,000
New +$1.37M 0.2% 96

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sphera Funds Management's DCPH Position: Q1 2021 in Review

Sphera Funds Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2021, closing a stake of 103,565 shares — an estimated $5.91M sold.

Sphera Funds Management first reported a position in DCPH in Q3 2017 and held it in 11 quarters. The position peaked at $17.6M in Q3 2020. 167 funds tracked by Wall St. Rank hold DCPH as of Q1 2021.

  • Sphera Funds Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Sphera Funds Management sold 103,565 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $5.91M.
  • Sphera Funds Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 11 quarters.
  • Sphera Funds Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $17.6M in Q3 2020.
  • 167 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.